Identification and validation of calmodulin as a binding protein of an anti-proliferative small molecule 3,4-dihydroisoquinolinium salt

Proteomics - Clinical Applications

Volumn 3, Issue 4, 2009, Pages 423-432

  Jung, Hye Jin ^a   Shim, Joong Sup ^a   Park, Jungchan ^b   Ha, Hyun Joon ^b   Kim, Jung Ho ^c   Kim, Joong Gon ^c   Kim, Nam Doo ^d   Yoon, Jeong Hyeok ^d   Kwon, Ho Jeong ^a  

^a Yonsei University   (South Korea)

^b Hankuk University of Foreign Studies   (South Korea)

^c Hanwha Corporation   (South Korea)

^d Equispharm Co Ltd   (South Korea)

Author keywords

Anti proliferative small molecule; Ca2+ CaM; Phage display; Target identification and validation

Indexed keywords

2 (2,5 DIFLUORBENZYL) 3,4 DIHYDRO 5 (10 HYDROXYDECYL) 6 METHOXY 1 UNDECYLISOQUINOLINIUM BROMIDE; CALMODULIN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOTOXIC AGENT; ISOQUINOLINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; BINDING COMPETITION; CALCIUM CELL LEVEL; CANCER CELL CULTURE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DNA LIBRARY; HUMAN; HUMAN CELL; MOLECULAR MODEL; PHAGE DISPLAY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE;

EID: 65549109049     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800060     Document Type: Article

References (33)

1. Schreiber, S. L., Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorg. Med. Chem. 1998, 6, 1127-1152.
2. Shim, J. S., Kwon, H. J., Chemical genetics for therapeutic target mining. Expert Opin. Ther. Targets 2004, 8, 653-661.
3. Brissette, R., Prendergast, J. K., Goldstein, N. I., Identification of cancer targets and therapeutics using phage display. Curr. Opin. Drug Discov. Devel. 2006, 9, 363-369.
4. Savinov, S. N., Austin, D. J., The cloning of human genes using cDNA phage display and small-molecule chemical probes. Comb. Chem. High Throughput Screen. 2001, 4, 593-597.
5. Piggott, A. M., Karuso, P., Quality, not quantity: the role of natural products and chemical proteomics in modern drug discovery. Comb. Chem. High Throughput Screen. 2004, 7, 607-630.
6. Piggott, A. M., Karuso, P., Quality not quantity: the role of marine natural products in drug discovery and reverse chemical proteomics. Mar. Drugs 2005, 3, 36-63.
7. Piggott, A. M., Karuso, P., Rapid identification of a protein binding partner for the marine natural product kahalalide F by using reverse chemical proteomics. Chembiochem. 2008, 9, 524-530.
8. Sche, P. P., McKenzie, K. M., White, J. D., Austin, D. J., Display cloning: functional identification of natural product receptors using cDNA-phage display. Chem. Biol. 1999, 6, 707-716.
9. Yu, X., Zhao, P., Zhang, W., Zhang, L. et al., Screening of phage displayed human liver cDNA library against dexamethasone. J. Pharm. Biomed. Anal. 2007, 45, 701-705.
10. 2+/calmodulin function. Chem. Biol. 2004, 11, 1455-1463.
11. Kim, J. H., Lee, S. P., Choi, J. Y., Paik, Y. K. et al., Korean Patent 2006, 10-0812843.
12. Cheung, W. Y., Calmodulin plays a pivotal role in cellular regulation. Science 1980, 207, 19-27.
13. Veigl, M. L., Vanaman, T. C., Sedwick, W. D., Calcium and calmodulin in cell growth and transformation. Biochim. Biophys. Acta 1984, 738, 21-48.
14. Carafoli, E., Calcium signaling: a tale for all seasons. Proc. Natl. Acad. Sci. USA 2002, 99, 1115-1122.
15. Nakayama, S., Kretsinger, R. H., Evolution of the EF-hand family of proteins. Annu. Rev. Biophys. Biomol. Struct. 1994, 23, 473-507.
16. Ikura, M., Clore, G. M., Gronenborn, A. M., Zhu, G. et al., Solution structure of a calmodulin-target peptide complex by multidimensional NMR. Science 1992, 256, 632-638.
17. Babu, Y. S., Sack, J. S., Greenhough, T. J., Bugg, C. E. et al., Three-dimensional structure of calmodulin. Nature 1985, 315, 37-40.
18. 2+/ calmodulin. Nat. Struct. Biol. 1994, 1, 795-801.
19. Osawa, M., Swindells, M. B., Tanikawa, J., Tanaka, T., Solution structure of calmodulin-W-7 complex: the basis of diversity in molecular recognition. J. Mol. Biol. 1998, 276, 165-176.
20. 2+, and calmodulin. Cell Signal. 2002, 14, 649-654.
21. Lee, M., Differential physiological effects of Raf-1 kinase pathways linked to protein kinase C activation depending on the stimulus in v-H-ras-transformed cells. Cancer Res. Treat. 2008, 40, 39-44.
22. Smith, G. P., Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228, 1315-1317.
23. Clackson, T., Wells, J. A., In vitro selection from protein and peptide libraries. Trends Biotechnol. 1994, 12, 173-184.
24. Jackson, A. E., Puett, D., Binding of trifluoperazine and fluorene-containing compounds to calmodulin and adducts. Biochem. Pharmacol. 1986, 35, 4395-4400.
25. Massom, L., Lee, H., Jarrett, H. W., Trifluoperazine binding to porcine brain calmodulin and skeletal muscle troponin C. Biochemistry 1990, 29, 671-681.
26. 2+/calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells. Biochem. Biophys. Res. Commun. 2007, 359, 747-751.
27. 2+-channel blocker verapamil on human lung cancer cell lines. Carcinogenesis 1991, 12, 2301-2303.
28. Strobl, J. S., Peterson, V. A., Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13. J. Pharmacol. Exp. Ther. 1992, 263, 186-193.
29. Wei, J. W., Morris, H. P., Hickie, R. A., Positive correlation between calmodulin content and hepatoma growth rates. Cancer Res. 1982, 42, 2571-2574.
30. Kahl, R. C., Means, A. R., Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocrine Rev. 2003, 24, 719-736.
31. Rodriguez-Mora, O. G., LaHair, M. M., Howe, C. J., McCubrey, J. A. et al., Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy. Expert Opin. Ther. Target. 2005, 9, 791-808.
32. Li, H., Sanchez-Torres, J., Del Carpio, A., Salas, V. et al., The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein. Biochem. J. 2004, 381, 257-266.
33. Hait, W. N., Targeting calmodulin for the development of novel cancer chemotherapeutic agents. Anticancer Drug Des. 1987, 2, 139-149.